Back to Our work

Pharmaceuticals & Medical Products

We are the leading consultancy for pharmaceutical and medical product companies. In the UK, we have supported clients on more than 300 projects in the past five years.

What we do

We are the industry’s leading consultancy on strategy, R&D, operations and commercial topics. The range of our work gives us a comprehensive perspective on the issues our clients face, such as how to:

  • Achieve growth
  • Prioritise R&D investments
  • Develop innovative and distinctive products
  • Capture the healthcare data opportunity.

Who we are

Our London office has more than 40 specialist healthcare consultants with advanced degrees in life science or medicine. To gain additional insights, we consult an extensive network of external experts who serve on our standing teams for different therapeutic areas, such as diabetes, oncology, central nervous system and other major disease areas. Overall, these advisory boards include more than 120 world-class external advisers who are leaders in their fields.
Knowledge and networks

We invest in primary research to create cutting-edge tools, training programmes and databases, such as:

  • Tools for benchmarking R&D performance (SuccessLab), commercial performance (Insights PharmaCo and Live Launch), clinical operations (Clinical Trial Impact), pharmaceutical operations (POBOS) and medical affairs (MAPES)
  • Best practices for improving the long-term performance and health of pharmaceutical companies, developed by drawing on more than 120,000 data points from our Organisational Health Index, which covers hundreds of companies across all industries
  • A proprietary tool to help clients identify patients with undiagnosed conditions by applying an advanced algorithm (Disease Analyser) to medical records, and follow up with patients via physician or nursing programmes.  
To learn more about our expertise, visit our global Pharmaceuticals & Medical Products Practice site.

Latest thinking

A wake-up call for Big Pharma
article | McKinsey Quarterly

A wake-up call for Big Pharma

Lower profit margins suggest a need for new business models.

Restoring biopharmaceutical R&D
article | McKinsey Quarterly

Restoring value to biopharmaceutical R&D

After years of seeing value destroyed by R&D excesses, biopharmaceutical companies can gain healthier returns—but only if they recognize several new imperatives.

Meet our people

Martin Dewhurst

Martin Dewhurst

Director

Brings 20 years of experience to helping companies shape and execute their globalisation strategies

Angela Spatharou

Angela Spatharou

Principal

Advises public-sector bodies and private corporations on integrated health management, consumer healthcare, disease prevention and behavioural change